Login to Your Account

Trimeris, ChemBridge Partner To Study HIV Entry Inhibitors

By Karen Pihl-Carey

Wednesday, June 15, 2005
For two years after gaining approval of its HIV product Fuzeon, Trimeris Inc. has worked to develop next-generation peptide fusion inhibitors, but now it will branch its HIV research into a whole new area - small molecules. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription